USA HEALTH UNIVERSITY HOSPITAL
- Type
- Teaching hospital
- Where
- Mobile, AL
- Medicare CCN
- 010087
- Received
- $983,666 in 316 records, 2020 ($54,488 general, $929,178 research)
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2020 | General payment | 9 | $54,488 |
| 2020 | Research payment | 307 | $929,178 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Merck Sharp & Dohme LLC | 223 | $565,133 | 2020 |
| Incyte Corporation | 72 | $158,188 | 2020 |
| JAZZ PHARMACEUTICALS INC. | 1 | $101,623 | 2020 |
| AstraZeneca Pharmaceuticals LP | 5 | $44,362 | 2020 |
| ABBVIE INC. | 4 | $39,355 | 2020 |
| Intuitive Surgical, Inc. | 4 | $36,356 | 2020 |
| Ipsen Bioscience Inc. | 1 | $19,515 | 2020 |
| GE HEALTHCARE | 3 | $12,064 | 2020 |
| B. Braun Medical Inc. | 1 | $6,036 | 2020 |
| Mallinckrodt Hospital Products Inc. | 1 | $1,000 | 2020 |
| Siemens Medical Solutions USA, Inc. | 1 | $32 | 2020 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 307 | $929,178 |
| Education | 4 | $36,356 |
| Consulting Fee | 3 | $12,064 |
| Gift | 1 | $6,036 |
| Charitable Contribution | 1 | $32 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2020-12-31 | Intuitive Surgical, Inc. | $16,840 | Education | In-kind items and services | Da Vinci Surgical System Device, SURGERY | 2020 | |
| 2020-12-31 | AstraZeneca Pharmaceuticals LP | $7,264 | Research payment | In-kind items and services | IMFINZI Drug, Oncology | A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Durvalumab Monotherapy or in Combinatio | 2020 |
| 2020-12-31 | Intuitive Surgical, Inc. | $2,720 | Education | In-kind items and services | Da Vinci Surgical System Device, SURGERY | 2020 | |
| 2020-12-31 | AstraZeneca Pharmaceuticals LP | $1,705 | Research payment | In-kind items and services | Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum Resistant Ovaria | 2020 | |
| 2020-12-31 | Siemens Medical Solutions USA, Inc. | $32 | Charitable Contribution | In-kind items and services | 2020 | ||
| 2020-12-30 | ABBVIE INC. | $21,480 | Research payment | Cash or cash equivalent | VENCLEXTA Drug, ONCOLOGY | M19-708 | 2020 |
| 2020-12-28 | Merck Sharp & Dohme LLC | $455 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for F | 2020 |
| 2020-12-22 | Incyte Corporation | $14,395 | Research payment | Cash or cash equivalent | A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in | 2020 | |
| 2020-12-22 | Merck Sharp & Dohme LLC | $9,623 | Research payment | Cash or cash equivalent | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for F | 2020 |
| 2020-12-22 | Incyte Corporation | $6,553 | Research payment | Cash or cash equivalent | A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in | 2020 | |
| 2020-12-22 | Incyte Corporation | $4,817 | Research payment | Cash or cash equivalent | A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in | 2020 | |
| 2020-12-22 | Incyte Corporation | $2,583 | Research payment | Cash or cash equivalent | A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in | 2020 | |
| 2020-12-22 | Incyte Corporation | $2,133 | Research payment | Cash or cash equivalent | A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in | 2020 | |
| 2020-12-22 | Incyte Corporation | $421 | Research payment | Cash or cash equivalent | A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in | 2020 | |
| 2020-12-21 | Merck Sharp & Dohme LLC | $19,541 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for F | 2020 |
| 2020-12-21 | Merck Sharp & Dohme LLC | $1,384 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for F | 2020 |
| 2020-12-17 | Merck Sharp & Dohme LLC | $6,103 | Research payment | Cash or cash equivalent | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for F | 2020 |
| 2020-12-15 | Merck Sharp & Dohme LLC | $6,143 | Research payment | Cash or cash equivalent | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for F | 2020 |
| 2020-12-10 | Merck Sharp & Dohme LLC | $6,103 | Research payment | Cash or cash equivalent | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for F | 2020 |
| 2020-12-10 | Merck Sharp & Dohme LLC | $750 | Research payment | Cash or cash equivalent | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for F | 2020 |
| 2020-12-08 | Merck Sharp & Dohme LLC | $45 | Research payment | In-kind items and services | MK-5890 Biological, ONCOLOGY | A Phase 1 Study of MK-5890 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumo | 2020 |
| 2020-12-08 | Merck Sharp & Dohme LLC | $38 | Research payment | In-kind items and services | MK-5890 Biological, ONCOLOGY | A Phase 1 Study of MK-5890 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumo | 2020 |
| 2020-12-08 | Merck Sharp & Dohme LLC | $32 | Research payment | In-kind items and services | MK-5890 Biological, ONCOLOGY | A Phase 1 Study of MK-5890 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumo | 2020 |
| 2020-12-08 | Merck Sharp & Dohme LLC | $19 | Research payment | In-kind items and services | MK-5890 Biological, ONCOLOGY | A Phase 1 Study of MK-5890 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumo | 2020 |
| 2020-12-08 | Merck Sharp & Dohme LLC | $13 | Research payment | In-kind items and services | MK-5890 Biological, ONCOLOGY | A Phase 1 Study of MK-5890 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumo | 2020 |
| 2020-11-25 | Merck Sharp & Dohme LLC | $8,695 | Research payment | Cash or cash equivalent | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for F | 2020 |
| 2020-11-25 | Mallinckrodt Hospital Products Inc. | $1,000 | Research payment | Cash or cash equivalent | STRATAGRAFT SKIN TISSUE IN THE PROMOTION OF AUTOLOGOUS SKIN REGENERATION OF COMPLEX SKIN DEFECTS DUE TO THERMAL BURNS TH | 2020 | |
| 2020-11-23 | Merck Sharp & Dohme LLC | $19,541 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for F | 2020 |
| 2020-11-10 | Merck Sharp & Dohme LLC | $45,597 | Research payment | In-kind items and services | MK-5890 Biological, ONCOLOGY | A Phase 1 Study of MK-5890 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumo | 2020 |
| 2020-11-10 | Merck Sharp & Dohme LLC | $6,500 | Research payment | Cash or cash equivalent | MK-7339 Drug, ONCOLOGY | A Phase 3 Study of Pembrolizumab MK-3475 in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab | 2020 |
| 2020-10-23 | Merck Sharp & Dohme LLC | $26,055 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in | 2020 |
| 2020-10-20 | Merck Sharp & Dohme LLC | $9,450 | Research payment | Cash or cash equivalent | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for F | 2020 |
| 2020-10-19 | Merck Sharp & Dohme LLC | $19,541 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for F | 2020 |
| 2020-10-14 | Merck Sharp & Dohme LLC | $1,129 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for F | 2020 |
| 2020-10-14 | Merck Sharp & Dohme LLC | $461 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for F | 2020 |
| 2020-10-08 | AstraZeneca Pharmaceuticals LP | $16,900 | Research payment | Cash or cash equivalent | A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial Chemoembolization (TACE) i | 2020 | |
| 2020-10-08 | Merck Sharp & Dohme LLC | $107 | Research payment | In-kind items and services | MK-5890 Biological, ONCOLOGY | A Phase 1 Study of MK-5890 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumo | 2020 |
| 2020-10-08 | Merck Sharp & Dohme LLC | $107 | Research payment | In-kind items and services | MK-5890 Biological, ONCOLOGY | A Phase 1 Study of MK-5890 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumo | 2020 |
| 2020-10-08 | Merck Sharp & Dohme LLC | $85 | Research payment | In-kind items and services | MK-5890 Biological, ONCOLOGY | A Phase 1 Study of MK-5890 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumo | 2020 |
| 2020-10-08 | Merck Sharp & Dohme LLC | $65 | Research payment | In-kind items and services | MK-5890 Biological, ONCOLOGY | A Phase 1 Study of MK-5890 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumo | 2020 |
| 2020-10-08 | Merck Sharp & Dohme LLC | $65 | Research payment | In-kind items and services | MK-5890 Biological, ONCOLOGY | A Phase 1 Study of MK-5890 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumo | 2020 |
| 2020-10-08 | Merck Sharp & Dohme LLC | $62 | Research payment | In-kind items and services | MK-5890 Biological, ONCOLOGY | A Phase 1 Study of MK-5890 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumo | 2020 |
| 2020-10-08 | Merck Sharp & Dohme LLC | $53 | Research payment | In-kind items and services | MK-5890 Biological, ONCOLOGY | A Phase 1 Study of MK-5890 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumo | 2020 |
| 2020-10-08 | Merck Sharp & Dohme LLC | $53 | Research payment | In-kind items and services | MK-5890 Biological, ONCOLOGY | A Phase 1 Study of MK-5890 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumo | 2020 |
| 2020-10-08 | Merck Sharp & Dohme LLC | $53 | Research payment | In-kind items and services | MK-5890 Biological, ONCOLOGY | A Phase 1 Study of MK-5890 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumo | 2020 |
| 2020-10-08 | Merck Sharp & Dohme LLC | $51 | Research payment | In-kind items and services | MK-5890 Biological, ONCOLOGY | A Phase 1 Study of MK-5890 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumo | 2020 |
| 2020-10-08 | Merck Sharp & Dohme LLC | $45 | Research payment | In-kind items and services | MK-5890 Biological, ONCOLOGY | A Phase 1 Study of MK-5890 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumo | 2020 |
| 2020-10-08 | Merck Sharp & Dohme LLC | $42 | Research payment | In-kind items and services | MK-5890 Biological, ONCOLOGY | A Phase 1 Study of MK-5890 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumo | 2020 |
| 2020-10-08 | Merck Sharp & Dohme LLC | $32 | Research payment | In-kind items and services | MK-5890 Biological, ONCOLOGY | A Phase 1 Study of MK-5890 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumo | 2020 |
| 2020-10-08 | Merck Sharp & Dohme LLC | $32 | Research payment | In-kind items and services | MK-5890 Biological, ONCOLOGY | A Phase 1 Study of MK-5890 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumo | 2020 |
| 2020-10-08 | Merck Sharp & Dohme LLC | $32 | Research payment | In-kind items and services | MK-5890 Biological, ONCOLOGY | A Phase 1 Study of MK-5890 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumo | 2020 |
| 2020-10-08 | Merck Sharp & Dohme LLC | $31 | Research payment | In-kind items and services | MK-5890 Biological, ONCOLOGY | A Phase 1 Study of MK-5890 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumo | 2020 |
| 2020-10-08 | Merck Sharp & Dohme LLC | $22 | Research payment | In-kind items and services | MK-5890 Biological, ONCOLOGY | A Phase 1 Study of MK-5890 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumo | 2020 |
| 2020-10-08 | Merck Sharp & Dohme LLC | $22 | Research payment | In-kind items and services | MK-5890 Biological, ONCOLOGY | A Phase 1 Study of MK-5890 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumo | 2020 |
| 2020-10-08 | Merck Sharp & Dohme LLC | $19 | Research payment | In-kind items and services | MK-5890 Biological, ONCOLOGY | A Phase 1 Study of MK-5890 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumo | 2020 |
| 2020-10-08 | Merck Sharp & Dohme LLC | $19 | Research payment | In-kind items and services | MK-5890 Biological, ONCOLOGY | A Phase 1 Study of MK-5890 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumo | 2020 |
| 2020-10-08 | Merck Sharp & Dohme LLC | $19 | Research payment | In-kind items and services | MK-5890 Biological, ONCOLOGY | A Phase 1 Study of MK-5890 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumo | 2020 |
| 2020-10-08 | Merck Sharp & Dohme LLC | $19 | Research payment | In-kind items and services | MK-5890 Biological, ONCOLOGY | A Phase 1 Study of MK-5890 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumo | 2020 |
| 2020-10-08 | Merck Sharp & Dohme LLC | $19 | Research payment | In-kind items and services | MK-5890 Biological, ONCOLOGY | A Phase 1 Study of MK-5890 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumo | 2020 |
| 2020-10-08 | Merck Sharp & Dohme LLC | $19 | Research payment | In-kind items and services | MK-5890 Biological, ONCOLOGY | A Phase 1 Study of MK-5890 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumo | 2020 |
| 2020-10-08 | Merck Sharp & Dohme LLC | $19 | Research payment | In-kind items and services | MK-5890 Biological, ONCOLOGY | A Phase 1 Study of MK-5890 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumo | 2020 |
| 2020-10-08 | Merck Sharp & Dohme LLC | $19 | Research payment | In-kind items and services | MK-5890 Biological, ONCOLOGY | A Phase 1 Study of MK-5890 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumo | 2020 |
| 2020-10-08 | Merck Sharp & Dohme LLC | $19 | Research payment | In-kind items and services | MK-5890 Biological, ONCOLOGY | A Phase 1 Study of MK-5890 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumo | 2020 |
| 2020-10-08 | Merck Sharp & Dohme LLC | $19 | Research payment | In-kind items and services | MK-5890 Biological, ONCOLOGY | A Phase 1 Study of MK-5890 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumo | 2020 |
| 2020-10-08 | Merck Sharp & Dohme LLC | $19 | Research payment | In-kind items and services | MK-5890 Biological, ONCOLOGY | A Phase 1 Study of MK-5890 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumo | 2020 |
| 2020-10-08 | Merck Sharp & Dohme LLC | $19 | Research payment | In-kind items and services | MK-5890 Biological, ONCOLOGY | A Phase 1 Study of MK-5890 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumo | 2020 |
| 2020-10-08 | Merck Sharp & Dohme LLC | $19 | Research payment | In-kind items and services | MK-5890 Biological, ONCOLOGY | A Phase 1 Study of MK-5890 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumo | 2020 |
| 2020-10-08 | Merck Sharp & Dohme LLC | $19 | Research payment | In-kind items and services | MK-5890 Biological, ONCOLOGY | A Phase 1 Study of MK-5890 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumo | 2020 |
| 2020-10-08 | Merck Sharp & Dohme LLC | $19 | Research payment | In-kind items and services | MK-5890 Biological, ONCOLOGY | A Phase 1 Study of MK-5890 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumo | 2020 |
| 2020-10-08 | Merck Sharp & Dohme LLC | $19 | Research payment | In-kind items and services | MK-5890 Biological, ONCOLOGY | A Phase 1 Study of MK-5890 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumo | 2020 |
| 2020-10-08 | Merck Sharp & Dohme LLC | $19 | Research payment | In-kind items and services | MK-5890 Biological, ONCOLOGY | A Phase 1 Study of MK-5890 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumo | 2020 |
| 2020-10-08 | Merck Sharp & Dohme LLC | $17 | Research payment | In-kind items and services | MK-5890 Biological, ONCOLOGY | A Phase 1 Study of MK-5890 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumo | 2020 |
| 2020-10-08 | Merck Sharp & Dohme LLC | $17 | Research payment | In-kind items and services | MK-5890 Biological, ONCOLOGY | A Phase 1 Study of MK-5890 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumo | 2020 |
| 2020-10-08 | Merck Sharp & Dohme LLC | $17 | Research payment | In-kind items and services | MK-5890 Biological, ONCOLOGY | A Phase 1 Study of MK-5890 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumo | 2020 |
| 2020-10-08 | Merck Sharp & Dohme LLC | $13 | Research payment | In-kind items and services | MK-5890 Biological, ONCOLOGY | A Phase 1 Study of MK-5890 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumo | 2020 |
| 2020-10-08 | Merck Sharp & Dohme LLC | $13 | Research payment | In-kind items and services | MK-5890 Biological, ONCOLOGY | A Phase 1 Study of MK-5890 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumo | 2020 |
| 2020-10-08 | Merck Sharp & Dohme LLC | $13 | Research payment | In-kind items and services | MK-5890 Biological, ONCOLOGY | A Phase 1 Study of MK-5890 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumo | 2020 |
| 2020-10-08 | Merck Sharp & Dohme LLC | $10 | Research payment | In-kind items and services | MK-5890 Biological, ONCOLOGY | A Phase 1 Study of MK-5890 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumo | 2020 |
| 2020-10-08 | Merck Sharp & Dohme LLC | $10 | Research payment | In-kind items and services | MK-5890 Biological, ONCOLOGY | A Phase 1 Study of MK-5890 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumo | 2020 |
| 2020-10-08 | Merck Sharp & Dohme LLC | $10 | Research payment | In-kind items and services | MK-5890 Biological, ONCOLOGY | A Phase 1 Study of MK-5890 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumo | 2020 |
| 2020-10-08 | Merck Sharp & Dohme LLC | $10 | Research payment | In-kind items and services | MK-5890 Biological, ONCOLOGY | A Phase 1 Study of MK-5890 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumo | 2020 |
| 2020-10-08 | Merck Sharp & Dohme LLC | $10 | Research payment | In-kind items and services | MK-5890 Biological, ONCOLOGY | A Phase 1 Study of MK-5890 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumo | 2020 |
| 2020-10-08 | Merck Sharp & Dohme LLC | $10 | Research payment | In-kind items and services | MK-5890 Biological, ONCOLOGY | A Phase 1 Study of MK-5890 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumo | 2020 |
| 2020-10-08 | Merck Sharp & Dohme LLC | $10 | Research payment | In-kind items and services | MK-5890 Biological, ONCOLOGY | A Phase 1 Study of MK-5890 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumo | 2020 |
| 2020-10-08 | Merck Sharp & Dohme LLC | $10 | Research payment | In-kind items and services | MK-5890 Biological, ONCOLOGY | A Phase 1 Study of MK-5890 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumo | 2020 |
| 2020-10-08 | Merck Sharp & Dohme LLC | $10 | Research payment | In-kind items and services | MK-5890 Biological, ONCOLOGY | A Phase 1 Study of MK-5890 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumo | 2020 |
| 2020-10-08 | Merck Sharp & Dohme LLC | $10 | Research payment | In-kind items and services | MK-5890 Biological, ONCOLOGY | A Phase 1 Study of MK-5890 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumo | 2020 |
| 2020-10-08 | Merck Sharp & Dohme LLC | $10 | Research payment | In-kind items and services | MK-5890 Biological, ONCOLOGY | A Phase 1 Study of MK-5890 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumo | 2020 |
| 2020-10-01 | B. Braun Medical Inc. | $6,036 | Gift | Cash or cash equivalent | VEIN VIEWER Device, VASCULAR ACCESS | 2020 | |
| 2020-10-01 | Incyte Corporation | $95 | Research payment | Cash or cash equivalent | A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in | 2020 | |
| 2020-09-30 | Intuitive Surgical, Inc. | $14,460 | Education | In-kind items and services | Da Vinci Surgical System Device, SURGERY | 2020 | |
| 2020-09-30 | Intuitive Surgical, Inc. | $2,335 | Education | In-kind items and services | Da Vinci Surgical System Device, SURGERY | 2020 | |
| 2020-09-29 | Merck Sharp & Dohme LLC | $15,607 | Research payment | Cash or cash equivalent | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for F | 2020 |
| 2020-09-29 | AstraZeneca Pharmaceuticals LP | $14,000 | Research payment | Cash or cash equivalent | IMFINZI Drug, Oncology | A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Durvalumab Monotherapy or in Combinatio | 2020 |
| 2020-09-17 | ABBVIE INC. | $175 | Research payment | Cash or cash equivalent | M14-239 | 2020 | |
| 2020-09-15 | JAZZ PHARMACEUTICALS INC. | $101,623 | Research payment | In-kind items and services | VYXEOS Drug, HEMATOLOGY/ONCOLOGY | A STUDY TO COMPARE STANDARD CHEMOTHERAPY TO THERAPY WITH CPX-351 AND/OR GILTERITINIB FOR PATIENTS WITH NEWLY DIAGNOSED A | 2020 |
| 2020-09-15 | Incyte Corporation | $421 | Research payment | Cash or cash equivalent | A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in | 2020 | |
| 2020-09-09 | Merck Sharp & Dohme LLC | $795 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for F | 2020 |
| 2020-09-08 | Merck Sharp & Dohme LLC | $12,206 | Research payment | Cash or cash equivalent | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for F | 2020 |
| 2020-09-08 | Merck Sharp & Dohme LLC | $8,000 | Research payment | Cash or cash equivalent | MK-7339 Drug, ONCOLOGY | A Phase 3 Study of Pembrolizumab MK-3475 in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab | 2020 |
| 2020-09-08 | Merck Sharp & Dohme LLC | $6,715 | Research payment | Cash or cash equivalent | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for F | 2020 |
| 2020-09-08 | Merck Sharp & Dohme LLC | $6,103 | Research payment | Cash or cash equivalent | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for F | 2020 |
| 2020-09-02 | Merck Sharp & Dohme LLC | $306 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in | 2020 |
| 2020-09-01 | Merck Sharp & Dohme LLC | $226 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for F | 2020 |
| 2020-09-01 | Incyte Corporation | $95 | Research payment | Cash or cash equivalent | A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in | 2020 | |
| 2020-08-27 | Incyte Corporation | $17,771 | Research payment | Cash or cash equivalent | A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in | 2020 | |
| 2020-08-27 | Incyte Corporation | $11,474 | Research payment | Cash or cash equivalent | A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in | 2020 | |
| 2020-08-27 | Incyte Corporation | $3,321 | Research payment | Cash or cash equivalent | A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in | 2020 | |
| 2020-08-25 | Incyte Corporation | $163 | Research payment | Cash or cash equivalent | A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in | 2020 | |
| 2020-08-20 | Incyte Corporation | $8,504 | Research payment | Cash or cash equivalent | A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in | 2020 | |
| 2020-08-10 | Merck Sharp & Dohme LLC | $103 | Research payment | In-kind items and services | MK-5890 Biological, ONCOLOGY | A Phase 1 Study of MK-5890 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumo | 2020 |
| 2020-08-10 | Incyte Corporation | $70 | Research payment | Cash or cash equivalent | A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in | 2020 | |
| 2020-08-10 | Merck Sharp & Dohme LLC | $50 | Research payment | In-kind items and services | MK-5890 Biological, ONCOLOGY | A Phase 1 Study of MK-5890 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumo | 2020 |
| 2020-08-10 | Incyte Corporation | $38 | Research payment | Cash or cash equivalent | A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in | 2020 | |
| 2020-08-10 | Merck Sharp & Dohme LLC | $13 | Research payment | In-kind items and services | MK-5890 Biological, ONCOLOGY | A Phase 1 Study of MK-5890 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumo | 2020 |
| 2020-08-01 | Incyte Corporation | $95 | Research payment | Cash or cash equivalent | A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in | 2020 | |
| 2020-07-30 | Merck Sharp & Dohme LLC | $6,025 | Research payment | Cash or cash equivalent | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for F | 2020 |
| 2020-07-30 | Merck Sharp & Dohme LLC | $1,885 | Research payment | Cash or cash equivalent | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for F | 2020 |
| 2020-07-21 | Merck Sharp & Dohme LLC | $6,103 | Research payment | Cash or cash equivalent | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for F | 2020 |
| 2020-07-21 | Merck Sharp & Dohme LLC | $6,103 | Research payment | Cash or cash equivalent | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for F | 2020 |
| 2020-07-21 | Merck Sharp & Dohme LLC | $6,103 | Research payment | Cash or cash equivalent | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for F | 2020 |
| 2020-07-21 | Merck Sharp & Dohme LLC | $6,103 | Research payment | Cash or cash equivalent | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for F | 2020 |
| 2020-07-21 | Merck Sharp & Dohme LLC | $6,103 | Research payment | Cash or cash equivalent | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for F | 2020 |
| 2020-07-21 | Merck Sharp & Dohme LLC | $5,167 | Research payment | Cash or cash equivalent | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for F | 2020 |
| 2020-07-14 | Merck Sharp & Dohme LLC | $4,821 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in | 2020 |
| 2020-07-09 | Merck Sharp & Dohme LLC | $73 | Research payment | In-kind items and services | MK-5890 Biological, ONCOLOGY | A Phase 1 Study of MK-5890 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumo | 2020 |
| 2020-07-09 | Merck Sharp & Dohme LLC | $50 | Research payment | In-kind items and services | MK-5890 Biological, ONCOLOGY | A Phase 1 Study of MK-5890 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumo | 2020 |
| 2020-07-09 | Merck Sharp & Dohme LLC | $32 | Research payment | In-kind items and services | MK-5890 Biological, ONCOLOGY | A Phase 1 Study of MK-5890 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumo | 2020 |
| 2020-07-09 | Merck Sharp & Dohme LLC | $21 | Research payment | In-kind items and services | MK-5890 Biological, ONCOLOGY | A Phase 1 Study of MK-5890 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumo | 2020 |
| 2020-07-09 | Merck Sharp & Dohme LLC | $21 | Research payment | In-kind items and services | MK-5890 Biological, ONCOLOGY | A Phase 1 Study of MK-5890 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumo | 2020 |
| 2020-07-09 | Merck Sharp & Dohme LLC | $19 | Research payment | In-kind items and services | MK-5890 Biological, ONCOLOGY | A Phase 1 Study of MK-5890 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumo | 2020 |
| 2020-07-09 | Merck Sharp & Dohme LLC | $19 | Research payment | In-kind items and services | MK-5890 Biological, ONCOLOGY | A Phase 1 Study of MK-5890 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumo | 2020 |
| 2020-07-09 | Merck Sharp & Dohme LLC | $19 | Research payment | In-kind items and services | MK-5890 Biological, ONCOLOGY | A Phase 1 Study of MK-5890 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumo | 2020 |
| 2020-07-09 | Merck Sharp & Dohme LLC | $19 | Research payment | In-kind items and services | MK-5890 Biological, ONCOLOGY | A Phase 1 Study of MK-5890 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumo | 2020 |
| 2020-07-09 | Merck Sharp & Dohme LLC | $19 | Research payment | In-kind items and services | MK-5890 Biological, ONCOLOGY | A Phase 1 Study of MK-5890 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumo | 2020 |
| 2020-07-09 | Merck Sharp & Dohme LLC | $19 | Research payment | In-kind items and services | MK-5890 Biological, ONCOLOGY | A Phase 1 Study of MK-5890 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumo | 2020 |
| 2020-07-09 | Merck Sharp & Dohme LLC | $19 | Research payment | In-kind items and services | MK-5890 Biological, ONCOLOGY | A Phase 1 Study of MK-5890 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumo | 2020 |
| 2020-07-09 | Merck Sharp & Dohme LLC | $19 | Research payment | In-kind items and services | MK-5890 Biological, ONCOLOGY | A Phase 1 Study of MK-5890 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumo | 2020 |
| 2020-07-09 | Merck Sharp & Dohme LLC | $19 | Research payment | In-kind items and services | MK-5890 Biological, ONCOLOGY | A Phase 1 Study of MK-5890 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumo | 2020 |
| 2020-07-09 | Merck Sharp & Dohme LLC | $19 | Research payment | In-kind items and services | MK-5890 Biological, ONCOLOGY | A Phase 1 Study of MK-5890 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumo | 2020 |
| 2020-07-09 | Merck Sharp & Dohme LLC | $19 | Research payment | In-kind items and services | MK-5890 Biological, ONCOLOGY | A Phase 1 Study of MK-5890 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumo | 2020 |
| 2020-07-09 | Merck Sharp & Dohme LLC | $10 | Research payment | In-kind items and services | MK-5890 Biological, ONCOLOGY | A Phase 1 Study of MK-5890 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumo | 2020 |
| 2020-07-09 | Merck Sharp & Dohme LLC | $10 | Research payment | In-kind items and services | MK-5890 Biological, ONCOLOGY | A Phase 1 Study of MK-5890 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumo | 2020 |
| 2020-07-09 | Merck Sharp & Dohme LLC | $10 | Research payment | In-kind items and services | MK-5890 Biological, ONCOLOGY | A Phase 1 Study of MK-5890 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumo | 2020 |
| 2020-07-09 | Merck Sharp & Dohme LLC | $10 | Research payment | In-kind items and services | MK-5890 Biological, ONCOLOGY | A Phase 1 Study of MK-5890 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumo | 2020 |
| 2020-07-09 | Merck Sharp & Dohme LLC | $10 | Research payment | In-kind items and services | MK-5890 Biological, ONCOLOGY | A Phase 1 Study of MK-5890 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumo | 2020 |
| 2020-07-09 | Merck Sharp & Dohme LLC | $10 | Research payment | In-kind items and services | MK-5890 Biological, ONCOLOGY | A Phase 1 Study of MK-5890 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumo | 2020 |
| 2020-07-09 | Merck Sharp & Dohme LLC | $10 | Research payment | In-kind items and services | MK-5890 Biological, ONCOLOGY | A Phase 1 Study of MK-5890 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumo | 2020 |
| 2020-07-09 | Merck Sharp & Dohme LLC | $10 | Research payment | In-kind items and services | MK-5890 Biological, ONCOLOGY | A Phase 1 Study of MK-5890 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumo | 2020 |
| 2020-07-09 | Merck Sharp & Dohme LLC | $10 | Research payment | In-kind items and services | MK-5890 Biological, ONCOLOGY | A Phase 1 Study of MK-5890 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumo | 2020 |
| 2020-07-09 | Merck Sharp & Dohme LLC | $10 | Research payment | In-kind items and services | MK-5890 Biological, ONCOLOGY | A Phase 1 Study of MK-5890 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumo | 2020 |
| 2020-07-09 | Merck Sharp & Dohme LLC | $10 | Research payment | In-kind items and services | MK-5890 Biological, ONCOLOGY | A Phase 1 Study of MK-5890 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumo | 2020 |
| 2020-07-09 | Merck Sharp & Dohme LLC | $10 | Research payment | In-kind items and services | MK-5890 Biological, ONCOLOGY | A Phase 1 Study of MK-5890 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumo | 2020 |
| 2020-07-07 | Merck Sharp & Dohme LLC | $5,897 | Research payment | Cash or cash equivalent | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for F | 2020 |
| 2020-07-07 | Merck Sharp & Dohme LLC | $5,897 | Research payment | Cash or cash equivalent | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for F | 2020 |
| 2020-07-07 | Merck Sharp & Dohme LLC | $5,897 | Research payment | Cash or cash equivalent | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for F | 2020 |
| 2020-07-01 | GE HEALTHCARE | $624 | Consulting Fee | Cash or cash equivalent | Device, LIFE CARE SOLUTIONS | 2020 | |
| 2020-07-01 | Incyte Corporation | $95 | Research payment | Cash or cash equivalent | A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in | 2020 | |
| 2020-06-30 | Merck Sharp & Dohme LLC | $6,715 | Research payment | Cash or cash equivalent | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for F | 2020 |
| 2020-06-25 | Merck Sharp & Dohme LLC | $752 | Research payment | In-kind items and services | MK-7339 Drug, ONCOLOGY | A Phase 3 Study of Pembrolizumab MK-3475 in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab | 2020 |
| 2020-06-09 | Merck Sharp & Dohme LLC | $7,686 | Research payment | Cash or cash equivalent | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for F | 2020 |
| 2020-06-04 | Incyte Corporation | $433 | Research payment | Cash or cash equivalent | A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in | 2020 | |
| 2020-06-01 | Incyte Corporation | $95 | Research payment | Cash or cash equivalent | A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in | 2020 | |
| 2020-05-27 | GE HEALTHCARE | $9,360 | Consulting Fee | Cash or cash equivalent | Device, LIFE CARE SOLUTIONS | 2020 | |
| 2020-05-27 | GE HEALTHCARE | $2,080 | Consulting Fee | Cash or cash equivalent | Device, LIFE CARE SOLUTIONS | 2020 | |
| 2020-05-08 | Incyte Corporation | $158 | Research payment | Cash or cash equivalent | A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in | 2020 | |
| 2020-05-08 | Incyte Corporation | $94 | Research payment | Cash or cash equivalent | A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in | 2020 | |
| 2020-05-08 | Incyte Corporation | $70 | Research payment | Cash or cash equivalent | A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in | 2020 | |
| 2020-05-08 | Incyte Corporation | $70 | Research payment | Cash or cash equivalent | A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in | 2020 | |
| 2020-05-08 | Incyte Corporation | $70 | Research payment | Cash or cash equivalent | A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in | 2020 | |
| 2020-05-08 | Incyte Corporation | $70 | Research payment | Cash or cash equivalent | A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in | 2020 | |
| 2020-05-08 | Incyte Corporation | $70 | Research payment | Cash or cash equivalent | A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in | 2020 | |
| 2020-05-08 | Incyte Corporation | $65 | Research payment | Cash or cash equivalent | A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in | 2020 | |
| 2020-05-08 | Incyte Corporation | $65 | Research payment | Cash or cash equivalent | A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in | 2020 | |
| 2020-05-08 | Incyte Corporation | $61 | Research payment | Cash or cash equivalent | A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in | 2020 | |
| 2020-05-08 | Incyte Corporation | $57 | Research payment | Cash or cash equivalent | A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in | 2020 | |
| 2020-05-08 | Incyte Corporation | $57 | Research payment | Cash or cash equivalent | A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in | 2020 | |
| 2020-05-08 | Incyte Corporation | $42 | Research payment | Cash or cash equivalent | A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in | 2020 | |
| 2020-05-08 | Incyte Corporation | $35 | Research payment | Cash or cash equivalent | A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in | 2020 | |
| 2020-05-08 | Incyte Corporation | $28 | Research payment | Cash or cash equivalent | A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in | 2020 | |
| 2020-05-08 | Incyte Corporation | $18 | Research payment | Cash or cash equivalent | A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in | 2020 | |
| 2020-05-08 | Incyte Corporation | $12 | Research payment | Cash or cash equivalent | A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in | 2020 | |
| 2020-05-08 | Incyte Corporation | $5 | Research payment | Cash or cash equivalent | A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in | 2020 | |
| 2020-05-08 | Incyte Corporation | $3 | Research payment | Cash or cash equivalent | A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in | 2020 | |
| 2020-05-08 | Incyte Corporation | $2 | Research payment | Cash or cash equivalent | A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in | 2020 | |
| 2020-05-08 | Incyte Corporation | $1 | Research payment | Cash or cash equivalent | A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in | 2020 | |
| 2020-05-07 | Merck Sharp & Dohme LLC | $240 | Research payment | In-kind items and services | MK-7339 Drug, ONCOLOGY | A Phase 3 Study of Pembrolizumab MK-3475 in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab | 2020 |
| 2020-05-01 | Incyte Corporation | $95 | Research payment | Cash or cash equivalent | A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in | 2020 | |
| 2020-04-23 | Merck Sharp & Dohme LLC | $15,998 | Research payment | Cash or cash equivalent | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for F | 2020 |
| 2020-04-21 | ABBVIE INC. | $200 | Research payment | Cash or cash equivalent | M14-239 | 2020 | |
| 2020-04-16 | ABBVIE INC. | $17,500 | Research payment | Cash or cash equivalent | M14-239 | 2020 | |
| 2020-04-09 | Incyte Corporation | $23 | Research payment | Cash or cash equivalent | Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Arginase Inhibitor INCB001158 (Formerly K | 2020 | |
| 2020-04-09 | Incyte Corporation | $23 | Research payment | Cash or cash equivalent | Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Arginase Inhibitor INCB001158 (Formerly K | 2020 | |
| 2020-04-08 | Merck Sharp & Dohme LLC | $73 | Research payment | In-kind items and services | MK-5890 Biological, ONCOLOGY | A Phase 1 Study of MK-5890 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumo | 2020 |
| 2020-04-02 | Incyte Corporation | $443 | Research payment | Cash or cash equivalent | A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in | 2020 | |
| 2020-04-01 | Incyte Corporation | $95 | Research payment | Cash or cash equivalent | A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in | 2020 | |
| 2020-03-31 | Merck Sharp & Dohme LLC | $2,883 | Research payment | Cash or cash equivalent | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for F | 2020 |
| 2020-03-24 | Incyte Corporation | $22,825 | Research payment | Cash or cash equivalent | A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in | 2020 | |
| 2020-03-24 | Incyte Corporation | $7,800 | Research payment | Cash or cash equivalent | A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in | 2020 | |
| 2020-03-23 | Ipsen Bioscience Inc. | $19,515 | Research payment | Cash or cash equivalent | ONIVYDE Drug, Oncology | A Randomized, Open-label Phase 2 Study of Nanoliposomal Irinotecan Nal-IRI-Containing Regimens Versus Nab-Paclitaxel Plu | 2020 |
The latest 200 records of 316.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Mobile, AL, county Mobile County, AL, state Alabama; placed by its city name.
| Measure | Place (city or town) Mobile, AL | County Mobile County, AL | State Alabama |
|---|---|---|---|
| Population B01003 | 203,416 | 412,590 | 5,086,768 |
| Population, 2020 census P1 | 187,041 | 414,809 | 5,024,279 |
| Median age B01002 | 37.3 | 38.5 | 39.3 |
| Under 18 B01001 | 22.2% | 23.3% | 22.2% |
| 65 and over B01001 | 17.4% | 17.3% | 17.8% |
| Households B11001 | 84,639 | 161,665 | 1,997,247 |
| Foreign born B05002 | 4.3% | 3.4% | 4.0% |
| Median household income B19013 | $53,558 | $58,880 | $63,999 |
| Median family income B19113 | $72,616 | $76,737 | $83,032 |
| Per capita income B19301 | $33,935 | $33,306 | $36,087 |
| Poverty rate B17001 | 18.4% | 16.2% | 15.6% |
| Unemployment rate B23025 | 5.6% | 5.3% | 4.7% |
| Civilian labor force B23025 | 97,023 | 190,406 | 2,367,787 |
| Mean commute (minutes) B08013 | 22.8 | 26.1 | 25.5 |
| Bachelor's degree or higher B15003 | 32.0% | 26.0% | 28.4% |
| Housing units B25001 | 98,380 | 186,082 | 2,337,265 |
| Owner-occupied B25003 | 54.0% | 66.0% | 70.2% |
| Renters B25003 | 46.0% | 34.0% | 29.8% |
| Median home value B25077 | $193,300 | $190,700 | $209,900 |
| Median gross rent B25064 | $1,068 | $1,052 | $1,007 |
| White, not Hispanic B03002 | 41.1% | 54.8% | 63.4% |
| Black B03002 | 50.2% | 35.7% | 25.6% |
| Hispanic or Latino B03002 | 3.7% | 3.5% | 5.6% |
| Asian B03002 | 2.2% | 2.2% | 1.4% |
| American Indian and Alaska Native B03002 | 0.1% | 0.3% | 0.3% |
Economy now FRED unemployment 3.5% in Sep 2026 (2.8% a year earlier); per capita personal income $59,754 in 2025, up 30% in five years (+4.7% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Mobile, AL.
Comments